Acacia Pharma Group has been awarded BEL Small Company of the Year 2020 by Euronext Brussels at its annual New Year’s Ceremony.
During 2020 the company gained approval for two products in the US. Barhemsys is an antiemetic for surgical patients to treat post-operative nausea & vomiting, and Byfavo is a rapid acting and reversible sedative for patients requiring moderate sedation to undergo short medical procedures. Barhemsys was launched in August and the company says it is in “the very final stages£ of the launch process for Byfavo.
Mike Bolinder, CEO of Acacia Pharma said: “Looking to the future, our strategy is to drive the sales of both products in the US through our own organization and we believe we are well positioned for success. This potential success has been recognized in the recent initiation of coverage of the company by the healthcare analysts at Jefferies, who included Acacia Pharma as one of their top European biopharma/biotech investment ideas for 2021. We are pleased with the progress we have been able to make during the last year, especially given the impact of the global Covid-19 pandemic during the same period.”
The BEL Small Company of the Year is awarded to a company that has demonstrated the highest relative increase in market capitalisation, within the BEL Small index in 2020. The award was announced by the CEO of Euronext Brussels, Vincent Van Dessel, in the presence of Vincent Van Peteghem, Belgian Deputy Prime Minister and Minister of Finance.
